Clinical Focus ›› 2023, Vol. 38 ›› Issue (8): 763-768.doi: 10.3969/j.issn.1004-583X.2023.08.016
-
Received:2023-02-28Online:2023-08-20Published:2023-09-28
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.08.016
| 肿瘤类型 | 信号通路 | 在肿瘤中所发挥的作用 |
|---|---|---|
| 肺癌[ | p38MAPK | 促进肿瘤增殖 |
| PI3/PTEN/AKT信号通路 | 促进肿瘤转移 | |
| 食管鳞状细胞癌[ | Src/GSK3β/STAT3信号通路 | 促进肿瘤转移 |
| ERK通路 | 促进肿瘤转移 | |
| 胃癌[ | TP53突变依赖方式通过p53失活 | 促进肿瘤转移 |
| TP53突变依赖方式通过TPEN下调 | 促进肿瘤增殖 | |
| 肝细胞性肝癌[ | FOXM1/PBK/β-catenin信号通路 | 促进肿瘤的发生 |
| 结直肠癌[ | MAPK-ERK通路 | 促进肿瘤的发生 |
| SRC阻断泛素化降解途径 | 促进肿瘤的发生 | |
| PBK在Ser250位点磷酸化PRPK | 促进肿瘤的转移 | |
| 前列腺癌[ | β-catenin-TCF/LEF信号通路 | 促进肿瘤转移 |
| 淋巴瘤[ | c-Myc-E2F1-PBK信号轴 | 参与肿瘤的生长 |
| JAK2/TOPK/H3信号通路 | 促进肿瘤增殖 | |
| 骨髓瘤 | IL-6/JAK/Stat3信号通路 | 促进肿瘤增殖和抑制肿瘤凋亡 |
| 乳腺癌[ | 在Ser10位点磷酸化H3 | 促进细胞增殖 |
| 香叶基糖基化信号通路 | 促进肿瘤细胞增殖 | |
| Hippo-YAP/TAZ信号通路 | 促进肿瘤细胞增殖 | |
| TGF-β1/Smad信号通路 | 促进上皮间质转化和肿瘤侵袭 | |
| NF-kB/Snail信号通路 | 促进上皮间质转化和肿瘤侵袭 | |
| 黑色素瘤[ | 磷酸化H2AX | 抑制肿瘤细胞凋亡 |
| 在Ser32c处磷酸化Prx1 | 抑制肿瘤细胞凋亡 | |
| 皮肤癌[ | 磷酸化JNK | 参与肿瘤的发生 |
| 肿瘤类型 | 信号通路 | 在肿瘤中所发挥的作用 |
|---|---|---|
| 肺癌[ | p38MAPK | 促进肿瘤增殖 |
| PI3/PTEN/AKT信号通路 | 促进肿瘤转移 | |
| 食管鳞状细胞癌[ | Src/GSK3β/STAT3信号通路 | 促进肿瘤转移 |
| ERK通路 | 促进肿瘤转移 | |
| 胃癌[ | TP53突变依赖方式通过p53失活 | 促进肿瘤转移 |
| TP53突变依赖方式通过TPEN下调 | 促进肿瘤增殖 | |
| 肝细胞性肝癌[ | FOXM1/PBK/β-catenin信号通路 | 促进肿瘤的发生 |
| 结直肠癌[ | MAPK-ERK通路 | 促进肿瘤的发生 |
| SRC阻断泛素化降解途径 | 促进肿瘤的发生 | |
| PBK在Ser250位点磷酸化PRPK | 促进肿瘤的转移 | |
| 前列腺癌[ | β-catenin-TCF/LEF信号通路 | 促进肿瘤转移 |
| 淋巴瘤[ | c-Myc-E2F1-PBK信号轴 | 参与肿瘤的生长 |
| JAK2/TOPK/H3信号通路 | 促进肿瘤增殖 | |
| 骨髓瘤 | IL-6/JAK/Stat3信号通路 | 促进肿瘤增殖和抑制肿瘤凋亡 |
| 乳腺癌[ | 在Ser10位点磷酸化H3 | 促进细胞增殖 |
| 香叶基糖基化信号通路 | 促进肿瘤细胞增殖 | |
| Hippo-YAP/TAZ信号通路 | 促进肿瘤细胞增殖 | |
| TGF-β1/Smad信号通路 | 促进上皮间质转化和肿瘤侵袭 | |
| NF-kB/Snail信号通路 | 促进上皮间质转化和肿瘤侵袭 | |
| 黑色素瘤[ | 磷酸化H2AX | 抑制肿瘤细胞凋亡 |
| 在Ser32c处磷酸化Prx1 | 抑制肿瘤细胞凋亡 | |
| 皮肤癌[ | 磷酸化JNK | 参与肿瘤的发生 |
| 名称 | 肿瘤类型 | 发挥作用 |
|---|---|---|
| HI-TOPK-032 | 结肠癌[ | 抑制肿瘤生长 |
| 成人T细胞白血病/淋巴瘤[ | 抑制肿瘤生长 | |
| 神经胶质瘤[ | 抑制肿瘤生长 | |
| 肾上腺皮质腺癌[ | 阻断肿瘤细胞增殖 | |
| 鼻咽癌[ | 导致肿瘤体积缩小 | |
| 泌乳素瘤[ | 抑制泌乳素瘤生长和泌乳素分泌 | |
| OTS514 | 急性髓系白血病[ | 抑制肿瘤生长 |
| 肺癌[ | 抑制肿瘤生长 | |
| 卵巢癌[ | 抑制肿瘤生长 | |
| OTS964 | 肺癌[ | 抑制肿瘤生长 |
| ADA-07 | 皮肤癌[ | 缩小肿瘤体积 |
| SKLB-C05 | 结直肠癌[ | 抑制肿瘤生长和转移 |
| 泮托拉唑/艾普拉唑 | 结直肠癌[ | 抑制肿瘤生长 |
| 1-苯基菲啶-6(5H )酮衍生物 | 结直肠癌[ | 抑制肿瘤生长 |
| 名称 | 肿瘤类型 | 发挥作用 |
|---|---|---|
| HI-TOPK-032 | 结肠癌[ | 抑制肿瘤生长 |
| 成人T细胞白血病/淋巴瘤[ | 抑制肿瘤生长 | |
| 神经胶质瘤[ | 抑制肿瘤生长 | |
| 肾上腺皮质腺癌[ | 阻断肿瘤细胞增殖 | |
| 鼻咽癌[ | 导致肿瘤体积缩小 | |
| 泌乳素瘤[ | 抑制泌乳素瘤生长和泌乳素分泌 | |
| OTS514 | 急性髓系白血病[ | 抑制肿瘤生长 |
| 肺癌[ | 抑制肿瘤生长 | |
| 卵巢癌[ | 抑制肿瘤生长 | |
| OTS964 | 肺癌[ | 抑制肿瘤生长 |
| ADA-07 | 皮肤癌[ | 缩小肿瘤体积 |
| SKLB-C05 | 结直肠癌[ | 抑制肿瘤生长和转移 |
| 泮托拉唑/艾普拉唑 | 结直肠癌[ | 抑制肿瘤生长 |
| 1-苯基菲啶-6(5H )酮衍生物 | 结直肠癌[ | 抑制肿瘤生长 |
| [1] |
Li S, Zhu F, Zykova T, et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway[J]. J Biol Chem, 2011, 286(34):29601-29609.
doi: 10.1074/jbc.M111.225813 pmid: 21715333 |
| [2] |
Nandi A, Tidwell M, Karp J, et al. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells[J]. Blood Cells Mol Dis, 2004, 32(1):240-245.
doi: 10.1016/j.bcmd.2003.10.004 URL |
| [3] |
Simons-Evelyn M, Bailey-Dell K, Toretsky JA, et al. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells[J]. Blood Cells Mol Dis, 2001, 27(5):825-829.
doi: 10.1006/bcmd.2001.0452 URL |
| [4] |
Zykova TA, Zhu F, Vakorina TI, et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity[J]. J Biol Chem, 2010, 285(38):29138-29146.
doi: 10.1074/jbc.M110.135905 pmid: 20647304 |
| [5] |
Abe Y, Takeuchi T, Kagawa-Miki L, et al. A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis[J]. J Mol Biol, 2007, 370(2):231-245.
doi: 10.1016/j.jmb.2007.04.067 pmid: 17512944 |
| [6] |
Dougherty JD, Garcia AD, Nakano I, et al. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase[J]. J Neurosci, 2005, 25(46):10773-10785.
doi: 10.1523/JNEUROSCI.3207-05.2005 pmid: 16291951 |
| [7] |
Han Z, Li L, Huang Y, et al. PBK/TOPK: a therapeutic target worthy of attention[J]. Cells, 2021, 10(2):371.
doi: 10.3390/cells10020371 URL |
| [8] |
Gaudet S, Branton D, Lue RA. Characterization of PDZ-binding kinase, a mitotic kinase[J]. Proc Natl Acad Sci USA, 2000, 97(10):5167-5172.
doi: 10.1073/pnas.090102397 pmid: 10779557 |
| [9] |
Fujibuchi T, Abe Y, Takeuchi T, et al. Expression and phosphorylation of TOPK during spermatogenesis[J]. Dev Growth Differ, 2005, 47(9):637-644.
doi: 10.1111/j.1440-169X.2005.00834.x pmid: 16316408 |
| [10] |
Park JH, Nishidate T, Nakamura Y, et al. Critical roles of T-LAK cell-originated protein kinase in cytokinesis[J]. Cancer Sci, 2010, 101(2):403-411.
doi: 10.1111/cas.2010.101.issue-2 URL |
| [11] |
Rizkallah R, Batsomboon P, Dudley GB, et al. Identification of the oncogenic kinase TOPK/PBK as a master mitotic regulator of C2H2 zinc finger proteins[J]. Oncotarget, 2015, 6(3):1446-1461.
pmid: 25575812 |
| [12] |
Shinde SR, Gangula NR, Kavela S, et al. TOPK and PTEN participate in CHFR mediated mitotic checkpoint[J]. Cell Signal, 2013, 25(12):2511-2517.
doi: 10.1016/j.cellsig.2013.08.013 pmid: 24012691 |
| [13] |
Ayllon V, O'Connor R. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response[J]. Oncogene, 2007, 26(24):3451-3461.
doi: 10.1038/sj.onc.1210142 pmid: 17160018 |
| [14] |
Park JH, Jeong YJ, Won HK, et al. Activation of TOPK by lipopolysaccharide promotes induction of inducible nitric oxide synthase through NF-kappaB activity in leukemia cells[J]. Cell Signal, 2014, 26(5):849-856.
doi: 10.1016/j.cellsig.2014.01.004 URL |
| [15] |
Lu H, Xiao J, Ke C, et al. TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ[J]. Cell Death Dis, 2019, 10(8):583.
doi: 10.1038/s41419-019-1805-9 pmid: 31378785 |
| [16] |
Ma H, Li Y, Wang X, et al. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma[J]. Cell Death Dis, 2019, 10(3):166.
doi: 10.1038/s41419-019-1415-6 pmid: 30778048 |
| [17] |
Chai Y, Xue H, Wu Y, et al. MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase[J]. Exp Ther Med, 2018, 15(6):4822-4828.
doi: 10.3892/etm.2018.6020 pmid: 29805502 |
| [18] |
Shih MC, Chen JY, Wu YC, et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer[J]. Oncogene, 2012, 31(19):2389-2400.
doi: 10.1038/onc.2011.419 pmid: 21996732 |
| [19] |
Li Y, Yang Z, Li W, et al. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun[J]. Oncotarget, 2016, 7(6):6748-6764.
doi: 10.18632/oncotarget.6826 pmid: 26745678 |
| [20] |
Jiang Y, Zhang J, Zhao J, et al. TOPK promotes metastasis of esophageal squamous cell carcinoma by activating the Src/GSK3beta/STAT3 signaling pathway via gamma-catenin[J]. BMC Cancer, 2019, 19(1):1264.
doi: 10.1186/s12885-019-6453-z |
| [21] |
Ohashi T, Komatsu S, Ichikawa D, et al. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma[J]. Br J Cancer, 2017, 116(2):218-226.
doi: 10.1038/bjc.2016.394 |
| [22] |
Yang YF, Pan YH, Cao Y, et al. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of beta-Catenin signaling in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(29):47195-47205.
doi: 10.18632/oncotarget.v8i29 URL |
| [23] |
Zhu F, Zykova TA, Kang BS, et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells[J]. Gastroenterology, 2007, 133(1):219-231.
doi: 10.1053/j.gastro.2007.04.048 pmid: 17631144 |
| [24] |
Xiao J, Duan Q, Wang Z, et al. Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon[J]. Oncotarget, 2016, 7(17):24483-24494.
doi: 10.18632/oncotarget.8231 pmid: 27016416 |
| [25] | Zykova TA, Zhu F, Wang L, et al. The T-LAK cell-originated protein kinase signal pathway promotes colorectal cancer metastasis[J]. EBio Medicine, 2017, 18:73-82. |
| [26] |
Brown-Clay JD, Shenoy DN, Timofeeva O, et al. PBK/TOPK enhances aggressive phenotype in prostate cancer via beta-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion[J]. Oncotarget, 2015, 6(17):15594-15609.
pmid: 25909225 |
| [27] |
Cote S, Simard C, Lemieux R. Regulation of growth-related genes by interleukin-6 in murine myeloma cells[J]. Cytokine, 2002, 20(3):113-120.
pmid: 12453469 |
| [28] |
Uchida E, Suwa S, Yoshimoto R, et al. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation[J]. Int J Oncol, 2019, 54(5):1785-1796.
doi: 10.3892/ijo.2019.4740 pmid: 30864683 |
| [29] |
Hu F, Gartenhaus RB, Zhao XF, et al. c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas[J]. Leuk Res, 2013, 37(4):447-454.
doi: 10.1016/j.leukres.2012.11.010 URL |
| [30] |
Wang K, Wei J, Ma J, et al. Phosphorylation of PBK/TOPK Tyr74 by JAK2 promotes Burkitt lymphoma tumor growth[J]. Cancer Lett, 2022, 544:215812.
doi: 10.1016/j.canlet.2022.215812 URL |
| [31] |
Ota A, Hanamura I, Karnan S, et al. Novel interleukin-6 inducible gene PDZ-binding kinase promotes tumor growth of multiple myeloma cells[J]. J Interferon Cytokine Res, 2020, 40(8):389-405.
doi: 10.1089/jir.2020.0111 URL |
| [32] |
Park JH, Lin ML, Nishidate T, et al. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer[J]. Cancer Res, 2006, 66(18):9186-9195.
doi: 10.1158/0008-5472.CAN-06-1601 URL |
| [33] |
Dou X, Wei J, Sun A, et al. PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation[J]. Cancer Cell Int, 2015, 15:27.
doi: 10.1186/s12935-015-0178-0 pmid: 25745361 |
| [34] |
Li J, Weinberg MS, Zerbini L, et al. The oncogenic TBX3 is a downstream target and mediator of the TGF-beta1 signaling pathway[J]. Mol Biol Cell, 2013, 24(22):3569-3576.
doi: 10.1091/mbc.e13-05-0273 URL |
| [35] |
Lee YJ, Park JH, Oh SM. TOPK promotes epithelial-mesenchymal transition and invasion of breast cancer cells through upregulation of TBX3 in TGF-beta1/Smad signaling[J]. Biochem Biophys Res Commun, 2020, 522(1):270-277.
doi: 10.1016/j.bbrc.2019.11.104 URL |
| [36] |
Lee YJ, Park JH, Oh SM. Activation of NF-kappaB by TOPK upregulates Snail/Slug expression in TGF-beta1 signaling to induce epithelial-mesenchymal transition and invasion of breast cancer cells[J]. Biochem Biophys Res Commun, 2020, 530(1):122-129.
doi: 10.1016/j.bbrc.2020.07.015 URL |
| [37] |
Zykova TA, Zhu F, Lu C, et al. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells[J]. Clin Cancer Res, 2006, 12(23):6884-6893.
doi: 10.1158/1078-0432.CCR-06-0410 pmid: 17145805 |
| [38] |
Oh SM, Zhu F, Cho YY, et al. T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation[J]. Cancer Res, 2007, 67(11):5186-5194.
doi: 10.1158/0008-5472.CAN-06-4506 URL |
| [39] |
Kim DJ, Li Y, Reddy K, et al. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth[J]. Cancer Res, 2012, 72(12):3060-3068.
doi: 10.1158/0008-5472.CAN-11-3851 pmid: 22523035 |
| [40] |
Joel M, Mughal AA, Grieg Z, et al. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo[J]. Mol Cancer, 2015, 14:121.
doi: 10.1186/s12943-015-0398-x pmid: 26081429 |
| [41] |
Kar A, Zhang Y, Yacob BW, et al. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC[J]. Endocr Relat Cancer, 2019, 26(10):765-778.
doi: 10.1530/ERC-19-0262 URL |
| [42] |
Wang MY, Lin ZR, Cao Y, et al. PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: Driving tumor growth via ROS signaling and correlating with patient survival[J]. Oncotarget, 2016, 7(18):26604-26616.
doi: 10.18632/oncotarget.v7i18 URL |
| [43] |
Ishikawa C, Senba M, Mori N. Mitotic kinase PBK/TOPK as a therapeutic target for adult T?cell leukemia/lymphoma[J]. Int J Oncol, 2018, 53(2):801-814.
doi: 10.3892/ijo.2018.4427 pmid: 29901068 |
| [44] |
Zhu K, Cheng X, Wang S, et al. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas[J]. Front Endocrinol (Lausanne), 2021, 12:706909.
doi: 10.3389/fendo.2021.706909 URL |
| [45] |
Park JH, Inoue H, Kato T, et al. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer[J]. Cancer Sci, 2017, 108(3):488-496.
doi: 10.1111/cas.2017.108.issue-3 URL |
| [46] |
Alachkar H, Mutonga M, Malnassy G, et al. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia[J]. Oncotarget, 2015, 6(32):33410-33425.
doi: 10.18632/oncotarget.5418 pmid: 26450903 |
| [47] |
Ikeda Y, Park JH, Miyamoto T, et al. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer[J]. Clin Cancer Res, 2016, 22(24):6110-6117.
pmid: 27334838 |
| [48] |
Pirovano G, Roberts S, Brand C, et al. [(18)F]FE-OTS964: A small molecule targeting TOPK for in vivo pet imaging in a glioblastoma xenograft model[J]. Mol Imaging Biol, 2019, 21(4):705-712.
doi: 10.1007/s11307-018-1288-6 pmid: 30357568 |
| [49] |
Gao G, Zhang T, Wang Q, et al. ADA-07 Suppresses solar ultraviolet-induced skin carcinogenesis by directly inhibiting TOPK[J]. Mol Cancer Ther, 2017, 16(9):1843-1854.
doi: 10.1158/1535-7163.MCT-17-0212 pmid: 28655782 |
| [50] |
Gao T, Hu Q, Hu X, et al. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis[J]. Cancer Lett, 2019, 445:11-23.
doi: S0304-3835(18)30737-7 pmid: 30590102 |
| [51] |
Zheng M, Luan S, Gao S, et al. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase[J]. Oncotarget, 2017, 8(24):39143-39153.
doi: 10.18632/oncotarget.16609 pmid: 28388576 |
| [52] |
Zeng X, Liu L, Zheng M, et al. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase[J]. Oncotarget, 2016, 7(16):22460-22473.
doi: 10.18632/oncotarget.7984 pmid: 26967058 |
| [53] |
Hu QF, Gao TT, Shi Y J, et al. Design, synthesis and biological evaluation of novel 1-phenyl phenanthridin-6(5H)-one derivatives as anti-tumor agents targeting TOPK[J]. Eur J Med Chem, 2019, 162:407-422.
doi: 10.1016/j.ejmech.2018.11.007 URL |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||